FDA Reviewing New Combination Therapy for Patients with MIBC
Muscle-invasive bladder cancer, representing approximately 25% of all bladder cancer cases, is typically managed with radical cystectomy combined with cisplatin-based...
MIBC
Muscle-invasive bladder cancer, representing approximately 25% of all bladder cancer cases, is typically managed with radical cystectomy combined with cisplatin-based...
